Topical and oral bexarotene
Dermatologic Therapy2013Vol. 26(5), pp. 400–403
Citations Over TimeTop 18% of 2013 papers
Abstract
Bexarotene is a retinoid that specifically binds retinoid X receptors and has numerous effects on cellular growth and differentiation. It is approved for the treatment of cutaneous T cell lymphoma both topically and systemically. Adverse effects include hyperlipidemia, central hypothyroidism, and neutropenia with bexarotene capsules, and an irritant dermatitis with bexarotene gel. With aggressive management of these potential side effects, bexarotene is an additional option in the armamentarium for management of cutaneous T cell lymphoma.
Related Papers
- → Response of CD30+ Large Cell Lymphoma of Skin to Bexarotene(2002)14 cited
- Follicular mycosis fungoides: successful treatment with oral bexarotene.(2004)
- → Treatment of Mycosis Fungoides with Denileukin Diftitox and Oral Bexarotene(2006)8 cited
- → Ligand Screening System for the RXRα Heterodimer Using the Fluorescence RXR Agonist CU-6PMN(2023)1 cited
- → Immunomodulatory effects of bexarotene on tumor-associated macrophages in patients with mycosis fungoides.(2017)